Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
we are moving up faster then you think!
Somebody bought 238,000 SKYE at 0.13... Woooooo BIG SPENDER!!!!! https://ih.advfn.com/stock-market/USOTC/skye-bioscience-qb-SKYE/trades
Well, whatever they said worked. I'll message back if I find a playback.
Thanks
They held an IR presentation this morning
Mar 9, 2021 7:00 am EST
H.C. Wainwright Global Life Sciences Conference
Can't be a delayed reaction to the additional board members. Hopefully something big to come.
What's driving the PPS up? Now 30% on very strong volume
Brilliant idea- to add an "e" to an existing company's name.
I think I'll start a new company
Maybe
The Forde Motor Company?
Applee?
Facebooke?
IMO, it was a really stupid decision to name the company Skye Bioscience when there was already a Sky Bioscience.
https://skyebioscience.com
http://www.skybioscience.com
Skye Bioscience Appoints Cannabinoid Science Experts Giovanni Appendino, PhD and Eduardo Muñoz, MD, PhD to Scientific Advisory Board
Mon, March 8, 2021, 8:39 AM
San Diego, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, announced today the appointment of scientific innovators and cannabinoid experts, Giovanni Appendino, PhD and Eduardo Muñoz, MD, PhD to its scientific advisory board.
“We are honored to welcome two of the world’s most influential thought leaders in cannabinoid science, Drs. Appendino and Muñoz, to our scientific advisory board as we continue to advance our research and deepen our understanding of cannabinoid-based medicines,” said Punit Dhillon, Chief Executive Officer of Skye Bioscience. “Their combined expertise, insights, and experience in developing cannabinoid-derived clinical candidates will be invaluable as we advance and broaden our pipeline.”
Dr. Appendino has researched natural products for over 40 years, leading to the discovery and isolation of over 200 novel compounds, including novel phytocannabinoids and chemistry for cannabinoid-derived molecules. He is a Professor of Organic Chemistry, Department of Pharmaceutical Sciences at the University of Eastern Piedmont, Novara, Italy, where his research activities focus on isolation, chemical modification, and bioactive natural products synthesis. In recognition of his research, he was awarded the Rhône-Poulenc Rorer Award of the Phytochemical Society of Europe in 1991, the Quilico Medal of the Italian Chemical Society in 2009 the Bruker Prize of the Phytochemical Society of Europe in 2014. In 2018, he was elected to the Italian Academy of Sciences for his achievements in chemistry.
Dr. Appendino has authored over 400 peer-reviewed articles, 15 book chapters, and 32 patents on natural products chemistry and bioactivity. He is Editor-in-Chief of the Journal Fitoterapia and editorial board member of the journals Acta Pharmaceutica Sinica B, Pharma Nutrition, Natural Products Research, Chinese Herbal Medicines, and the book series Progress in the Chemistry of Organic Natural Products.
Dr. Muñoz has over 35 years of experience in biomedical research, focused on cannabinoids, pharmacology, and inflammation, providing deep expertise in the mechanism of actions of cannabinoids and the development of new cannabinoid-based chemical entities. He is a Professor of Immunology, Department of Cell Biology, Physiology and Immunology of the University of Córdoba, Spain, and Director of the inflammation and cancer research group at the Institute Maimonides for Biomedical Research Córdoba.
Dr. Muñoz has authored of over 300 articles, book chapters, patents, and is an editorial board member of journals Planta Medica, and Fitoterapia. He is also the co-founder of two biotech companies, VivaCell Biotechnology (now Emerald Biotechnology) and InnoHealth Group (now part of Evonik Industries GmbH).
Dr's. Appendino & Muñoz will serve alongside Skye’s world-class ophthalmology advisory board, comprised of Jeffrey Goldberg, MD, Ph.D., Professor and Chair, Department of Ophthalmology, Byers Eye Institute at Stanford University; Louis Pasquale, MD, FARVO, Professor of Ophthalmology at the Icahn School of Medicine, Chair of the Department of Ophthalmology and Vice-Chair of Translational Ophthalmology Research, Mount Sinai; and Robert Ritch, MD, Shelley, and Steven Einhorn Distinguished Chair, Surgeon Director Emeritus and Chief of Glaucoma Services at the New York Eye & Ear Infirmary of Mount Sinai.
I will play, I will put in a huge buy order.
You know the drill.
EMBI Price is 9.802 USD today.
1 year Skye Bioscience Forecast: 9.654019 *
5 year Skye Bioscience Forecast: 10.724 *
Alert! Please note that this asset seems fundamentally flawed meaning that we can't recommend investing it. This could be for various reasons: abandoned by the developers, faulty code, intentionally malicious project, etc.
About the Emerald Bioscience, Inc. stock forecast
As of 2021 March 06, Saturday current price of EMBI stock is 9.802$ and our data indicates that the asset price has been stagnating for the past 1 year (or since its inception).
Emerald Bioscience, Inc. has been showing a declining tendency so we believe that similar market segments were mildly popular in the given time frame.
Our site uses a custom algorithm based on Deep Learning that helps our users to decide if EMBI could be a good portfolio addition. These predictions take several variables into account such as volume changes, price changes, market cycles, similar stocks.
Future price of the stock is predicted at 9.654019$ (30.78% ) after a year according to our prediction system.
This means that if you invested $100 now, your current investment may be worth 130.78$ on 2022 March 06, Sunday.
This means that this stock is suited as a new addition to your portfolio as trading bullish markets is always a lot easier.
Skye Bioscience stock forecast, EMBI price prediction: Buy or sell Emerald Bioscience, Inc. shares?
by Gov Capital
EMBI Price is 9.802 USD today.
1 year Skye Bioscience Forecast: 9.654019 *
5 year Skye Bioscience Forecast: 10.724 *
No fable true story. Holding onto my shares like it’s platinum.
From The Article; David Stone said it best;
How to beat Wall Street:
You buy. And you hold. You hold forever. You never, ever sell until your thesis plays out. If the stock drops, you should be thrilled. You can buy more at a cheaper price. You should laugh like an invincible warrior facing down an army.
“You want this stock? You want MY STOCK? Then you’re gonna have to kill me and dig up the cemetery because I am taking this stock to the grave.”
If you hold on to your shares, Wall Street can never own them.
This will frustrate them. If enough investors buy and hold a stock because it’s a great company with great growth prospects, then the vampire squid will move on.
Wall Street’s biggest weapon is fear. Fear in the face of an uncertain future.
If you sell, they win.
If you hold, you win.
Don’t let Wall Street steal your gems.”
All, buy some. Give it u push for a fresh start monday !!!
Yea, this is my only OTC that has held up. Everything else has been bloody . I think we are ready for our next leg up here.
Funny, nobody is selling. All red, we are holding up. This is going to be something next week, when stocks will rise.
Good time to buy here. I plan on being here for a while. I expect some strong momentum soon.
GL
Finaly order went, thank you for the shares.
Could be fake walls today,
That’s how we win. Slow and steady wins the race. Product innovation and pioneering cannabinoid use will get us there.
I closed five positions with a high, could be, factor. The passed three weeks, were not realy funny on OTC, so I am going for a slower but sure pace. In EMBI/SKYE for one year now. And ready for the jump. GLTA
Let’s gain on positive proceeds!
I am done, loaded up. Now we can go up !
SKYE to 1 dollar by Q3-Q4, perhaps even earlier than that!
There is no call... it's just hold pattern or sideways with downward trend... load up under .08
Please do not add on my comment, make your own investements, no pump here. I think somebody made a mistake and put it online.
The reason I am buying/adding is... a think a saw a wrong share prediction update. Was 1$. Thats why I started 6 mnth ago. Or it was a typo, or this is going nuts. BTW, When is the call? Tomorrow?
reverse up
just added....
Meet you all on the MOON once SKYE reaches that $1 dollar.
I did mean University of Mississippi. Thank You!
If you mean University of Mississippi, no. Skye will be funding the trials (unless they get some sort of Gov't grant/funding).
Does anyone know if SKYE's clinical trials will be funded by MSU?
Thanks and good luck!
Good write up
Skye Bioscience Is Pursuing A New Kind Of Glaucoma Drug
https://finance.yahoo.com/news/skye-bioscience-pursuing-kind-glaucoma-140237389.html
Holding support well between 0.1150 and 0.13... Floor going in good opportunity to add.. looking good..
LOAD UP CANNABIS IS ON FIRE!!!!!!!
RM swell in progress...SKYE to a $1.00..bombshell_glaucoma_player.
Thanks for the shares.. Flippers gonna get smoked... Little Profit takers..
imo...first mj glaucoma patent..this ss...$5.00target...risky_flip.
ALL ABOARD!!!! (SKYE) PRICE IS CHURNING.... LOADING ZONE / LOAD UP.. UP TREND.
May see a 0.13 close here today...BOLLY BANDs ARE SMOKING...
Followers
|
138
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
6315
|
Created
|
11/12/14
|
Type
|
Free
|
Moderators |
Our lead candidate, THCVHS, a proprietary prodrug of tetrahydrocannabinol (THC), is a topical formulation under development for the treatment of glaucoma and ocular hypertension (OHT).
Previous US government studies in humans discovered that THC was able to reduce intraocular pressure (IOP), which is in part responsible for the crush-like injury to the cells of the optic nerve that can eventually result in blindness. Additional preclinical studies have shown the potential for THC to also provide neuroprotective benefit, which may be especially important to patients with glaucoma who are experiencing disease progression with normal IOP levels.
One of the major drawbacks of previous studies of the use of THC for glaucoma was that they relied on inhalation or ingestion of THC. These systemic routes of drug administration cause negative side effects like psychotropic effects and potentially decreasing blood pressure , which resulted in the American Academy of Opthamology determining that the adverse effects of systemic cannabis administration/consumption outweighed its therapeutic benefit.
At Skye Bioscience, we chemically modify THC to create a unique synthetic molecule with the intent to safely realize the known positive effects of THC. Our molecule enables enhanced local delivery in the eye, reduced systemic side effects, and the potential for neuroprotection for the treatment of ocular diseases.
Glaucoma is a group of eye diseases that can cause vision loss and blindness by damaging a nerve in the back of the eye called the optic nerve. Damage to the optic nerve is caused by increased intraocular pressure (IOP) due to improper drainage and/or overproduction of fluid in the eye.
According to the American Academy of Ophthalmology, glaucoma affects over 75million people worldwide and is the leading cause of blindness in adults aged 60 and older.
Current therapies can lower IOP but progressive tolerance requires switching or combining drugs. They do NOT provide neuroprotective capabilities.
In preclinical studies, Skye’s THCVHS demonstrated the potential to significantly reduce intraocular pressure (IOP) – exceeding the capabilities of leading commercialized drugs in the current glaucoma market.
Additionally, it has been demonstrated:
We develop novel and proprietary classes of synthetic molecules through the modification of naturally derived systems.
Shifting the solutions paradigm on a effective treatment of diseases through the development of novel neuroprotective solutions.
Science First
The foundation of Skye Bioscience.
Revolutionary Solutions
Solving unmet needs of diseases with limited treatment offerings.
Product-led
Commercial differentiated applications to provide therapeutic benefits.
Impact driven
Change makers. Platform solutions that can extend beyond a single disease.
Mr. Dhillon was the co-founder, CEO, and director of OncoSec Medical Inc., a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors.
Mr. Diep brings more than 15 years of scientific and clinical research experience to Skye Bioscience. Prior to joining Skye, Mr. Diep was at Protox Therapeutics Inc.
Richard has more than 30 years of business experience and served as a Vice President to CFO on multiple companies in a wide range of industries both public and private, domestic and international.
Mr. Kim serves as the General Counsel and Director of IP at Emerald Bioscience. He is an experienced biotech executive and corporate attorney, and a registered patent attorney.
Karam Takhar serves as Vice President, Corporate Development & Investor Relations at Skye Bioscience Inc. Prior to joining Skye, Mr. Takhar was at Emerald Health Sciences.
Mr. Dhillon was the co-founder, CEO, and director of OncoSec Medical Inc., a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors.
Mr. Heppell is the co-founder, President and Director of BC Advantage Funds (VCC) Ltd., a venture fund that invests in and builds technology, life science and clean technology companies.
Dr. Dalesandro is the President of Brecon Pharma Consulting, a full-service biotech consultancy firm focused on identifying and obtaining critical information early in product development.
Dr. Muñoz is a Professor of Immunology in the Department of Cell Biology, Physiology, and Immunology of the University of Córdoba, Spain.
Dr. Pasquale is a Professor of Organic Chemistry, Department of Pharmaceutical Sciences at the University of Eastern Piedmont, Novara, Italy, where his research activities focus on isolation ..
Dr. Goldberg is the Professor and Chair of Ophthalmology and Director of the Spencer Center for Vision Research at the Byers Eye Institute at Stanford University.
Dr. Pasquale is the Professor of Ophthalmology at the Icahn School of Medicine at Mount Sinai in New York City.
Dr. Ritch holds the Shelley and Steven Einhorn Distinguished Chair in Ophthalmology and is Clinical Professor of Ophthalmology at the Mt. Sinai Medical School and Surgeon Director Emeritus.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |